Allakos Inc. Faces Delisting Notice Following Merger with Concentra Biosciences
Allakos Inc. has received a delisting notice following its merger with Concentra Biosciences. The company requested Nasdaq to suspend trading of its shares before the market opened on May 15, 2025, and to file for removal from listing. Additionally, Allakos plans to terminate the registration of its shares with the SEC under the Securities Exchange Act of 1934.
Allakos Inc. announced a regulatory development concerning its listing status following the completion of a merger with Concentra Biosciences, LLC. As part of the merger consummation, Allakos requested The Nasdaq Global Select Market to suspend trading of its shares effective before the market opened on May 15, 2025. Additionally, the company requested Nasdaq to file a Notification of Removal from Listing to delist all its shares and deregister them under Section 12(b) of the Securities Exchange Act of 1934. Furthermore, the Surviving Corporation plans to file a Certification and Notice of Termination of Registration with the SEC, aiming to terminate the registration of its shares under Section 12(g) of the Exchange Act.
